Figure 4
Sorted T-ALL subsets engraft in NS122 xenografts. (A) Five primary T-ALL samples were sorted for CD34 and CD7 expression, then injected intrafemorally into NS122 recipients. Cell dose for each subset ranged from 3 × 104 to 2.5 × 106 cells with the cell dose determined previously by limiting dilution analysis. At least 2 recipients were injected for each T-ALL subset from each T-ALL sample. Engraftment was determined by flow cytometric analysis to detect human CD45+CD7+CD5+ cells in recipient RF. Each dot represents the percentage of human CD45+CD7+CD5+ cells from 1 recipient. The bar represents the mean percentage of CD45+CD7+CD5+ cells for each T-ALL sample. The CD34+CD7+ subset from 1 of 5 T-ALL samples engrafted in NS122 mice. (B) The CD34−CD7+ subset from 4 of 5 T-ALL samples engrafted in NS122 recipients. (C) T-ALL 0549 did not have any immunophenotype changes after engraftment in NS122 mice. Sorted CD34+CD7+CD1a− cells from T-ALL 0549 engrafted in NS122 recipients with both CD34+CD7+CD1a− and CD34−CD7+CD1a− cells, reconstituting the original immunophenotype of the patient T-ALL.

Sorted T-ALL subsets engraft in NS122 xenografts. (A) Five primary T-ALL samples were sorted for CD34 and CD7 expression, then injected intrafemorally into NS122 recipients. Cell dose for each subset ranged from 3 × 104 to 2.5 × 106 cells with the cell dose determined previously by limiting dilution analysis. At least 2 recipients were injected for each T-ALL subset from each T-ALL sample. Engraftment was determined by flow cytometric analysis to detect human CD45+CD7+CD5+ cells in recipient RF. Each dot represents the percentage of human CD45+CD7+CD5+ cells from 1 recipient. The bar represents the mean percentage of CD45+CD7+CD5+ cells for each T-ALL sample. The CD34+CD7+ subset from 1 of 5 T-ALL samples engrafted in NS122 mice. (B) The CD34CD7+ subset from 4 of 5 T-ALL samples engrafted in NS122 recipients. (C) T-ALL 0549 did not have any immunophenotype changes after engraftment in NS122 mice. Sorted CD34+CD7+CD1a cells from T-ALL 0549 engrafted in NS122 recipients with both CD34+CD7+CD1a and CD34CD7+CD1a cells, reconstituting the original immunophenotype of the patient T-ALL.

Close Modal

or Create an Account

Close Modal
Close Modal